Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/164999| Title: | Cost-effectiveness of insulin degludec versus insulin glargine U100 in patients with type 1 and type 2 diabetes in Portugal: evidence from SWITCH 1&2 trials |
| Author: | Darbà, Josep Ascanio, Meritxell Carvalho, Davide Conde, Vasco Pedersen, Kasper S. |
| Keywords: | Anàlisi cost-benefici Salut pública Diabetis Insulina Portugal Cost effectiveness Public health Diabetes Insulin Portugal |
| Issue Date: | 20-Dec-2019 |
| Publisher: | Cortex - Publicacoes Tecnicas e Cientificas |
| Abstract: | Objectives: To assess the cost-effectiveness of insulin degludec (degludec) versus insulin glargine (glargine) U100 from a Portuguese healthcare perspective using data from SWITCH 1 & 2 trials. - - - Methods: A short-term model estimated cost-effectiveness of degludec versus glargine U100 in type 1 diabetes (T1DM) basal bolus (B/B) and type 2 diabetes (T2DM) basal oral therapy (BOT) patients. The model captured hypoglycaemia rates and insulin dosing. Clinical outcomes were obtained from SWITCH 1 & 2. Disutilities related to hypoglycaemic events and insulin, needles and blood glucose tests costs were also included. Benefits were measured in QALYs. One-way and probabilistic sensitivity analyses were conducted (...) |
| Note: | Versió postprint del document publicat a: http://www.revportdiabetes.com/rpd-dez-2019/ |
| It is part of: | Revista Portuguesa de Diabetes, 2019, vol. 14, num. 4, p. 141-150 |
| URI: | http://hdl.handle.net/2445/164999 |
| ISSN: | 1646-3439 |
| Appears in Collections: | Articles publicats en revistes (Economia) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 695776.pdf | 540.18 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License
